-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
HBV-IN-8
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2724224-57-9.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 2724224-57-9 |
| Description | HBV-IN-8 is a potent inhibitor of HBV with an EC50 of 287.9 nM. (Extracted from patent WO2021213445A1, compound 13) |
Product Information
| Synonyms | 4-Piperidineacetic acid, 1-[5-[5-[[(3-chloro-4-fluorophenyl)amino]carbonyl]tetrahydro-6-methyl-1,1-dioxido-2H-1,2,6-thiadiazin-3-yl]-2-thiazolyl]- |
| IUPAC Name | 2-[1-[5-[5-[(3-chloro-4-fluorophenyl)carbamoyl]-6-methyl-1,1-dioxo-1,2,6-thiadiazinan-3-yl]-1,3-thiazol-2-yl]piperidin-4-yl]acetic acid |
| Molecular Weight | 546.04 |
| Molecular Formula | C21H25ClFN5O5S2 |
| Canonical SMILES | CN1C(CC(NS1(=O)=O)C2=CN=C(S2)N3CCC(CC3)CC(=O)O)C(=O)NC4=CC(=C(C=C4)F)Cl |
| InChI | InChI=1S/C21H25ClFN5O5S2/c1-27-17(20(31)25-13-2-3-15(23)14(22)9-13)10-16(26-35(27,32)33)18-11-24-21(34-18)28-6-4-12(5-7-28)8-19(29)30/h2-3,9,11-12,16-17,26H,4-8,10H2,1H3,(H,25,31)(H,29,30) |
| InChIKey | KFPIFAJKHLBVGQ-UHFFFAOYSA-N |
| Purity | ≥98% (HPLC) |
| Solubility | 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 888 |
| Exact Mass | 545.0969671 |
| Target | HBV |
| XLogP3-AA | 2.3 |
